IRLAB Therapeutics

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Polar Capital Global Healthcare Trust – executive interview

Quadrise – executive interview

Take on Trusts – November 2024

About Edison

About Edison

Careers

IRLAB Therapeutics (OMX: IRLAB-A)

Latest Insights

IRLAB Therapeutics — Progress across the pipeline in Q324

IRLAB Therapeutics — IRL757 progress prompts $2.5m milestone payment

IRLAB Therapeutics — IRL757 starts strong in Phase I

IRLAB Therapeutics — Pirepemat Phase IIb trial completes enrolment

Sector

Equity Analyst

Key Management

IRLAB Therapeutics — External validation boosts quarterly recap

IRLAB Therapeutics — MSRD agreement early validation for IRL757

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis

IRLAB Therapeutics — FDA thumbs up to mesdopetam’s Phase III plan

IRLAB Therapeutics — Mesdopetam’s potential highlighted in PD-psychosis

IRLAB Therapeutics — Positive FDA mesdopetam outlook following EoP2

IRLAB Therapeutics — Timeline refresh with numerous inflection points

IRLAB Therapeutics — End-of-Phase II FDA meeting set

IRLAB Therapeutics — SEK55m loan enhances headroom past key catalysts

IRLAB Therapeutics — IRL757 Phase I-ready with support from MJFF

IRLAB Therapeutics — Mesdopetam’s clinical roadmap laid out

IRLAB Therapeutics — Increased legroom for pirepemat with new patent

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Quarterly update recapping active pipeline plans

IRLAB Therapeutics — Collaboration to support FDA Ph III progression

IRLAB Therapeutics — Numerous clinical platform activities under way

IRLAB Therapeutics — Despite shift, mesdopetam still on track for Ph III

IRLAB Therapeutics — Phase IIb pirepemat obtains safety milestone

IRLAB Therapeutics — On track for pirepemat in Phase IIb

IRLAB Therapeutics — Collaboration bolsters CNS assets and platform

IRLAB Therapeutics — Positive signs for mesdopetam in Q1 update

IRLAB Therapeutics — Mesdopetam remains in Ipsen’s portfolio

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Don’t count mesdopetam out

IRLAB Therapeutics — Cautious update on portfolio timelines

IRLAB Therapeutics — Mesdopetam Phase IIb top-line data

IRLAB Therapeutics — Candidate selected to further bolster pipeline

IRLAB Therapeutics — Phase IIb trial patient follow-up as expected

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Mesdopetam top-line data readout approaches

IRLAB Therapeutics — Phase IIb recruitment complete

IRLAB Therapeutics — Ipsen confirms commitment with clinical studies

IRLAB Therapeutics — All steady as key catalyst approaches

IRLAB Therapeutics — Phase IIb/III mesdopetam study expanded

IRLAB Therapeutics — Clinical pipeline is tip of the iceberg

IRLAB Therapeutics — Richard Godfrey appointed as new CEO

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Screening platform continues to bear fruit

IRLAB Therapeutics — Looking beyond mesdopetam

IRLAB Therapeutics — Pirepemat and platform potential come into focus

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics — Platform validated, pipeline momentum building

IRLAB Therapeutics — Platform validated, pipeline momentum building

IRLAB Therapeutics — Ipsen deal de-risks the strategy

IRLAB Therapeutics — Global licensing deal for mesdopetam

IRLAB Therapeutics — Focused on novel Parkinson’s disease treatments